FDA clears Mirada's radiation oncology AI software

The U.S. Food and Drug Administration (FDA) has cleared artificial intelligence (AI) software for radiation oncology treatment planning from imaging software developer Mirada Medical.

The company's deep-learning contouring software, DLCExpert, helps users delineate critical structures on CT scans of patients. Typically a time-consuming task, the software reduces the time required by 75%, according to Mirada.

The FDA cleared DLCExpert as part of Mirada's Workflow Box 2.0 Zero-Click platform, where it is an option along with five additional workflows, including multimodality autocontouring, data routing, and custom application support. DLCExpert received the CE Mark for the European market earlier this year, the company said.

Page 1 of 462
Next Page